Reece Armstrong sits down with Dr Paul Peter Tak, venture partner at Flagship Pioneering and the former senior vice president of R&D, development leader and chief immunology officer at GSK to gain a global perspective on Brexit and pharma.
Nick Beckett, managing partner and co-head of CMS Life Sciences & Healthcare Group writes about China’s approach to attracting global pharmaceutical and digital health companies.
Senior professional support lawyer Paul England and Matthew Royle, partner in the life sciences team at international law firm Taylor Wessing discuss what the introduction of a manufacturing waiver to the SPC legislation means for manufacturers.
Rich Quelch, global head of marketing, Origin, looks at how Brexit will affect regulatory bodies in the UK and how this impacts pharmaceutical packagers.
With the end result of Brexit fast approaching, labelling supplier Kallik looks at the implications Brexit could place on labelling and compliance in the pharmaceutical sector.
With the potential of antimicrobial resistance (AMR) taking our modern medicine practices back to the stone age, governments around the world need to face the threat head on.
Jared Kimble, life sciences product specialist consultant at DXC Technology, writes about how regulatory intelligence can be utilised by life science companies.
Partner and patent attorney at intellectual property firm, Withers & Rogers, Dr Nicholas Jones, discusses why drug companies should continue to pursue new medical patents in the future, despite recent examples of legal disputes.
